(VIANEWS) – The Market ended the session with HYLORIS (HYL.BR) jumping 20.84% to €5.74 on Monday, after five consecutive sessions in a row of losses. BEL 20 slid 0.01% to €4,244.62, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.
HYLORIS’s last close was €4.75, 66.31% under its 52-week high of €14.10.
About HYLORIS
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Earnings Per Share
As for profitability, HYLORIS has a trailing twelve months EPS of €-0.55.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.08%.
More news about HYLORIS (HYL.BR).
